Saskia Kuhl

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas.

LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas.

Journal: Oncotarget
Published: November 07, 2025

Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.

Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.

Journal: Anticancer research
Published: January 29, 2025

LET-7a and LET-7b as Potential Signatures for Glioma Recurrence, Regardless of WHO Tumor Grade.

LET-7a and LET-7b as Potential Signatures for Glioma Recurrence, Regardless of WHO Tumor Grade.

Journal: Anticancer research
Published: May 02, 2024

Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma.

Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma.

Journal: Anticancer research
Published: February 28, 2024

Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.

Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.

Journal: Anticancer research
Published: November 01, 2021

Expression of ENO1 Is Up-regulated in Low-grade Glioma and Positively Correlated With Meningioma Grade.

Expression of ENO1 Is Up-regulated in Low-grade Glioma and Positively Correlated With Meningioma Grade.

Journal: Anticancer research
Published: June 05, 2021

TERT and its binding protein: overexpression of GABPA/B in high grade gliomas.

TERT and its binding protein: overexpression of GABPA/B in high grade gliomas.

Journal: Oncotarget
Published: November 13, 2020

Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.

Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.

Journal: Anticancer research
Published: April 09, 2019

Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.

Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.

Journal: World neurosurgery
Published: March 13, 2019

Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.

Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.

Journal: Anticancer research
Published: September 13, 2017
Showing 1-10 of 10

Last Updated: 09/26/2026